Mitochondrial myopathy

Mitochondrial myopathy is a group of neuromuscular disorders caused by dysfunction of the mitochondria — the energy-producing structures within cells. Because mitochondria are responsible for generating the majority of cellular energy (ATP) through oxidative phosphorylation, tissues with high energy demands, particularly skeletal muscle, are preferentially affected. Mitochondrial myopathies may occur in isolation or as part of broader multisystem mitochondrial syndromes. They can result from mutations in either mitochondrial DNA (mtDNA) or nuclear DNA genes that encode mitochondrial proteins. Key clinical features include progressive muscle weakness, exercise intolerance, fatigue, and sometimes muscle pain (myalgia). Patients frequently experience difficulty with sustained physical activity and may develop ptosis (drooping eyelids) and progressive external ophthalmoplegia (limited eye movements). Depending on the specific genetic defect, other organ systems may also be involved, including the central nervous system (seizures, ataxia, cognitive impairment), heart (cardiomyopathy, conduction defects), endocrine system (diabetes mellitus), and sensory organs (sensorineural hearing loss, retinal degeneration). Lactic acidosis, detectable on blood testing, is a common biochemical finding due to impaired aerobic metabolism. There is currently no cure for mitochondrial myopathy. Treatment is largely supportive and symptomatic, focusing on physical therapy, aerobic exercise training within tolerance, and management of complications such as cardiac or endocrine dysfunction. Nutritional supplements including coenzyme Q10, L-carnitine, riboflavin, and alpha-lipoic acid are commonly used, though evidence for their efficacy remains limited. Avoidance of mitochondrial toxins (such as certain medications including valproic acid and aminoglycoside antibiotics) is important. Genetic counseling is essential given the variable inheritance patterns. Research into gene therapy and novel pharmacological approaches is ongoing.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Mitochondrial myopathy